Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” (Lung Cancer (2017) 108 (228–231), (S0169500217302908), (10.1016/j.lungcan.2017.04.003));Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G769S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Lung Cancer

Volumn 108, Issue , 2017, Pages 228-231

  Ou, Sai Hong Ignatius ^a   Cui, Jean ^b   Schrock, Alexa B ^c   Goldberg, Michael E ^c   Zhu, Viola W ^a,d   Albacker, Lee ^c   Stephens, Philip J ^c   Miller, Vincent A ^c   Ali, Siraj M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TP Therapeutics Inc   (United States)

^c FOUNDATION MEDICINE   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

ctDNA assay; EGFR C797; EGFR G796; EGFR L792; EGFR+ lung cancer; Osimertinib; Solvent front mutation

Indexed keywords

ALK PROTEIN; CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLYCINE; LEUCINE; NEUROTROPHIN 3 RECEPTOR; OSIMERTINIB; PROTEIN; PROTEIN TYROSINE KINASE A; ROS1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CLAVICLE FRACTURE; CODON; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NODULE; LYMPHADENOPATHY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SHOULDER PAIN; TREATMENT RESPONSE; TUMOR BIOPSY; WHOLE BRAIN RADIOTHERAPY; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL; CANCER STAGING; CHEMISTRY; CONFORMATION; DISEASE MODEL; GENETICS; LUNG TUMOR; MOLECULAR MODEL; MUTATION;

AGED; ALLELES; AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEOPLASM STAGING; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85018584810     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2019.08.013     Document Type: Erratum

References (18)

1. [1] Cross, D.A., Ashton, S.E., Ghiorghiu, S., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4 (2014), 1046–1061.
2. [2] Khozin, S., Weinstock, C., Blumenthal, G.M., et al. Osimertinib for the treatment of metastatic epidermal growth factor T970M positive non-small cell lung cancer. Clin. Cancer Res.(December), 2016 Epub ahead of print.
3. [3] Mok, T.S., Wu, Y.L., Ahn, M.J., et al. Osimertinib or platinum-pemetrexed in EGFR T790M- positive lung cancer. N. Engl. J. Med.(December), 2016 Epub ahead of print.
4. [4] Ou, S.I., Young, L., Schrock, A.B., et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. J. Thorac. Oncol. 12 (2017), 137–140.
5. [5] Thress, K.S., Paweletz, C.P., Felip, E., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
6. [6] Yu, H.A., Tian, S.K., Drilon, A.E., et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR Inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 1 (2015), 982–984.
7. [7] Ou, S.H., Agarwal, N., Ali, S.M., High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer 98 (2016), 59–61.
8. [8] Chabon, J.J., Simmons, A.D., Lovejoy, A.F., et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun., 7(June), 2016, 11815.
9. [9] Ortiz-Cuaran, S., Scheffler, M., Plenker, D., et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin. Cancer Res. 22 (2016), 4837–4847.
10. [10] Lin, J.J., Fairclough, S.R., Nagly, R.J., et al. Identification of on-target mechanisms of resistance to EGFR inhibitors using cfDNA next-generation sequencing. 16th World Conference in Lung Cancer, Vienna, Austria, 2016 Abstract 5645.
11. [11] Niederst, M.J., Hu, H., Mulvey, H.E., et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21 (2015), 3924–3933.
12. [12] Yeh, P., Chen, H., Andrews, J., et al. DNA-mutation inventory to refine and enhance cancer treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin. Cancer Res. 19 (2013), 1894–1901.
13. [13] Ou, S.H., Azada, M., Hsiang, D.J., et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J. Thorac. Oncol. 9 (2014), 549–553.
14. [14] Awad, M.M., Katayama, R., McTigue, M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368 (2013), 2395–2401.
15. [15] Russo, M., Misale, S., Wei, G., et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 6 (2016), 36–44.
16. [16] Drilon, A., Li, G., Dogan, S., et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann. Oncol. 27 (2016), 920–926.
17. [17] Chen, K., Zhou, F., Shen, W., et al. Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osiemrtinib in advanced NSCLC. J. Thorac. Oncol., 2017 Epub ahead of print.
18. [18] Shaw, A.T., Friboulet, L., Leshchiner, I., et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374 (2016), 54–61.